Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk of scar in the comparison of age-related macular degeneration treatments trials.

Ophthalmology - 1 Mar 2014

Daniel Ebenezer, Toth Cynthia A, Grunwald Juan E, Jaffe Glenn J, Martin Daniel F, Fine Stuart L, Huang Jiayan, Ying Gui-shuang, Hagstrom Stephanie A, Winter Katrina, Maguire Maureen G

Abstract excerpt

OBJECTIVE: To describe risk factors for scar in eyes treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD). DESIGN: Prospective cohort study within a randomized clinical trial. PARTICIPANTS: Patients with no scar on color fundus photography (CFP) or fluore...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Bevacizumab
Share to Cicatrix

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorescein Angiography

Share to Intravitreal Injections

Share to Postoperative Complications

Share to Tomography, Optical Coherence

Share to Wet Macular Degeneration

Source

Open in PubMed Open full text

Identifiers

PMID: 24314839
DOI: 10.1016/j.ophtha.2013.10.019
PMCID: PMC3943618

Genes

CFP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24314839-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk of scar in the comparison of age-related macular degeneration treatments trials.PMID 24314839Read ↗

Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.Semantic proximity Read ↗

Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study.Semantic proximity Read ↗

Drusen Characteristics of Type 2 Macular Neovascularization in Age-related Macular DegenerationSemantic proximity Read ↗

Incidence of retinal pigment epithelium tears after intravitreal injection of Bevacizumab for the treatment of exudative age-related macular degenerationSemantic proximity Read ↗

Early prediction of macular neovascularization phenotypes and prognostic evolution.Semantic proximity Read ↗

Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17.Semantic proximity Read ↗

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.Semantic proximity Read ↗

Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Risk assessment model for development of advanced age-related macular degeneration.Semantic proximity Read ↗

Persistent Cytotoxic Immune Signaling in Anti-VEGF–Treated Neovascular Age-Related Macular DegenerationSemantic proximity Read ↗

Correlation of Color Fundus Photograph Grading with Risks of Early Age-related Macular Degeneration by using Automated OCT-derived Drusen Measurements.Semantic proximity Read ↗

Incidence and progression of geographic atrophy: observations from a population-based cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.